Works matching AU Savitz, Adam

Results: 28

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 528, doi. 10.1002/cpdd.290

By:

Remmerie, Bart;
Meulder, Marc;
Weiner, Sveta;
Savitz, Adam

Publication type:

Article

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 538, doi. 10.1002/cpdd.291

By:

Remmerie, Bart;
Meulder, Marc;
Ariyawansa, Jay;
Savitz, Adam

Publication type:

Article

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia.

Published in:

JAMA Psychiatry, 2015, v. 72, n. 8, p. 830, doi. 10.1001/jamapsychiatry.2015.0241

By:

Berwaerts, Joris;
Yarning Liu;
Gopal, Srihari;
Nuamah, Isaac;
Haiyan Xu;
Savitz, Adam;
Coppola, Danielle;
Schotte, Alain;
Remmerie, Bart;
Maruta, Nataliya;
Hough, David W.

Publication type:

Article

A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.

Published in:

Journal of Clinical & Experimental Neuropsychology, 2010, v. 32, n. 9, p. 937, doi. 10.1080/13803391003596496

By:

Silverstein, StevenM.;
Jaeger, Judith;
Donovan-Lepore, Anne-Marie;
Wilkniss, SandraM.;
Savitz, Adam;
Malinovsky, Igor;
Hawthorne, Danielle;
Raines, Shane;
Carson, Sarah;
Marcello, Stephanie;
Zukin, StephenR.;
Furlong, Stephen;
Dent, Gersham

Publication type:

Article

Response to Commentaries.

Published in:

Schizophrenia Bulletin, 2025, v. 51, n. 2, p. 287, doi. 10.1093/schbul/sbae227

By:

Horan, William P;
Kalali, Amir;
Brannan, Stephen K;
Drevets, Wayne;
Mahableshwarkar, Atul;
Rao, Srinivas;
Reuteman-Fowler, Corey;
Savitz, Adam;
Singh, Jaskaran;
Walker, Gary;
Wendland, Jens R;
Harvey, Philip D

Publication type:

Article

Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials.

Published in:

Schizophrenia Bulletin, 2025, v. 51, n. 2, p. 262, doi. 10.1093/schbul/sbae151

By:

Horan, William P;
Kalali, Amir;
Brannan, Stephen K;
Drevets, Wayne;
Leoni, Matthew;
Mahableshwarkar, Atul;
Martin, William J;
Rao, Srinivas;
Reuteman-Fowler, Corey;
Sauder, Colin;
Savitz, Adam;
Singh, Jaskaran;
Tiller, Jane;
Walker, Gary;
Wendland, Jens R;
Harvey, Philip D

Publication type:

Article

Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

Published in:

Schizophrenia Bulletin, 2018, v. 44, n. 6, p. 1204, doi. 10.1093/schbul/sbx163

By:

Anderson, Ariana E;
Marder, Stephen;
Reise, Steven P;
Savitz, Adam;
Salvadore, Giacomo;
Fu, Dong Jing;
Li, Qingqin;
Turkoz, Ibrahim;
Han, Carol;
Bilder, Robert M

Publication type:

Article

Attention Shaping: a Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia.

Published in:

Schizophrenia Bulletin, 2009, v. 35, n. 1, p. 222, doi. 10.1093/schbul/sbm150

By:

Silverstein, Steven M.;
Spaulding, William D.;
Menditto, Anthony A.;
Savitz, Adam;
Liberman, Robert P.;
Berten, Sarah;
Starobin, Hannah

Publication type:

Article

Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.

Published in:

British Journal of Clinical Pharmacology, 2016, v. 82, n. 5, p. 1364, doi. 10.1111/bcp.13050

By:

Samtani, Mahesh N.;
Nandy, Partha;
Ravenstijn, Paulien;
Remmerie, Bart;
Vermeulen, An;
Russu, Alberto;
D'hoore, Peter;
Baum, Ellen Z.;
Savitz, Adam;
Gopal, Srihari;
Hough, David

Publication type:

Article

Characteristics of patients with major depressive disorder switching SSRI/SNRI therapy compared with those augmenting with an atypical antipsychotic in a real-world setting.

Published in:

Current Medical Research & Opinion, 2021, v. 37, n. 8, p. 1377, doi. 10.1080/03007995.2021.1911975

By:

Kern, David M.;
Cepeda, M. Soledad;
Castilla-Puentes, Ruby C.;
Savitz, Adam;
Etropolski, Mila

Publication type:

Article

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.

Published in:

Neuropsychiatric Disease & Treatment, 2020, v. 16, p. 1533, doi. 10.2147/NDT.S221242

By:

Mathews, Maju;
Gopal, Srihari;
Singh, Arun;
Nuamah, Isaac;
Pungor, Katalin;
Tan, Wilson;
Soares, Bernardo;
Kim, Edward;
Savitz, Adam J

Publication type:

Article

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.

Published in:

Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 1365, doi. 10.2147/NDT.S197225

By:

Mathews, Maju;
Gopal, Srihari;
Nuamah, Isaac;
Hargarter, Ludger;
Savitz, Adam J;
Kim, Edward;
Tan, Wilson;
Soares, Bernardo;
Correll, Christoph U

Publication type:

Article

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.

Published in:

Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 731, doi. 10.2147/NDT.S194264

By:

Nash, Abigail I;
Turkoz, Ibrahim;
Savitz, Adam J;
Mathews, Maju;
Kim, Edward

Publication type:

Article

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Published in:

Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 587, doi. 10.2147/NDT.S189668

By:

Savitz, Adam J;
Xu, Haiyan;
Gopal, Srihari;
Nuamah, Isaac;
Ravenstijn, Paulien;
Hough, David;
Hargarter, Ludger

Publication type:

Article

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.

Published in:

Neuropsychiatric Disease & Treatment, 2018, v. 14, p. 2807, doi. 10.2147/NDT.S175364

By:

Mathews, Maju;
Nuamah, Isaac;
Savitz, Adam J;
Hough, David W;
Najarian, Dean;
Kim, Edward;
Gopal, Srihari

Publication type:

Article

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.

Published in:

Neuropsychiatric Disease & Treatment, 2017, v. 13, p. 2193, doi. 10.2147/NDT.S134287

By:

Savitz, Adam J.;
Haiyan Xu;
Gopal, Srihari;
Nuamah, Isaac;
Ravenstijn, Paulien;
Hough, David;
Mathews, Maju;
Yu Feng;
Lu Yu;
Masayoshi Takahashi;
Dennis Liu;
Gang Wang;
Jin-Sang Yoon;
Jiahn Jyh Chen

Publication type:

Article

Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia.

Published in:

Neuropsychopharmacology, 2009, v. 34, n. 8, p. 1885, doi. 10.1038/npp.2009.26

By:

Marx, Christine E.;
Keefe, Richard S. E.;
Buchanan, Robert W.;
Hamer, Robert M.;
Kilts, Jason D.;
Bradford, Daniel W.;
Strauss, Jennifer L.;
Naylor, Jennifer C.;
Payne, Victoria M.;
Lieberman, Jeffrey A.;
Savitz, Adam J.;
Leimone, Linda A.;
Dunn, Lawrence;
Porcu, Patrizia;
Morrow, A. Leslie;
Shampine, Lawrence J.

Publication type:

Article

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.

Published in:

Brazilian Journal of Psychiatry / Revista Brasileira de Psiquiatria, 2019, v. 41, n. 6, p. 499, doi. 10.1590/1516-4446-2018-0153

By:

Savitz, Adam J.;
Haiyan Xu;
Gopal, Srihari;
Nuamah, Isaac;
Mathews, Maju;
Soares, Bernardo

Publication type:

Article

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.

Published in:

International Journal of Neuropsychopharmacology, 2021, v. 24, n. 12, p. 965, doi. 10.1093/ijnp/pyab050

By:

Savitz, Adam;
Wajs, Ewa;
Zhang, Yun;
Xu, Haiyan;
Etropolski, Mila;
Thase, Michael E;
Drevets, Wayne C

Publication type:

Article

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.

Published in:

International Journal of Neuropsychopharmacology, 2016, v. 19, n. 7, p. 1, doi. 10.1093/ijnp/pyw018

By:

Savitz, Adam J.;
Haiyan Xu;
Gopal, Srihari;
Nuamah, Isaac;
Ravenstijn, Paulien;
Janik, Adam;
Schotte, Alain;
Hough, David;
Fleischhacker, Wolfgang W.

Publication type:

Article

Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia.

Published in:

2016

By:

Pierce, Phillip;
Gopal, Srihari;
Savitz, Adam;
Qiu, Hong;
Hino, Takahito;
Busch, Michelle;
Fujino, Akiko;
Mathews, Maju;
Katsu, Takeshi;
Maeda, Yoshikazu;
Takahashi, Masayoshi;
Hough, David

Publication type:

journal article

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.

Published in:

2015

By:

Gopal, Srihari;
Vermeulen, An;
Nandy, Partha;
Ravenstijn, Paulien;
Nuamah, Isaac;
Buron Vidal, José Antonio;
Berwaerts, Joris;
Savitz, Adam;
Hough, David;
Samtani, Mahesh N.;
Buron Vidal, José Antonio

Publication type:

journal article

Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.

Published in:

Clinical Drug Investigation, 2018, v. 38, n. 8, p. 695, doi. 10.1007/s40261-018-0647-z

By:

Mathews, Maju;
Pei, Huiling;
Savitz, Adam;
Nuamah, Isaac;
Hough, David;
Alphs, Larry;
Gopal, Srihari

Publication type:

Article

Reduced top‐down influences in contour detection in schizophrenia.

Published in:

Cognitive Neuropsychiatry, 2006, v. 11, n. 2, p. 112, doi. 10.1080/13546800444000209

By:

Silverstein, Steven;
Hatashita‐Wong, Michi;
Schenkel, Lindsay;
Wilkniss, Sandra;
Kovács, Ilona;
Fehér, Akos;
Smith, Thomas;
Goicochea, Claudia;
Uhlhaas, Peter;
Carpiniello, Kelly;
Savitz, Adam

Publication type:

Article

Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients.

Published in:

Psychological Medicine, 2005, v. 35, n. 6, p. 829, doi. 10.1017/S0033291704003356

By:

STEVEN M. SILVERSTEIN;
MICHI HATASHITA-WONG;
BETH ANNE SOLAK;
PETER UHLHAAS;
YULIA LANDA;
SANDRA M. WILKNISS;
CLAUDIA GOICOCHEA;
KELLY CARPINIELLO;
LINDSAY S. SCHENKEL;
ADAM SAVITZ;
THOMAS E. SMITH

Publication type:

Article

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.

Published in:

Journal of Clinical Pharmacology, 2016, v. 56, n. 3, p. 330, doi. 10.1002/jcph.597

By:

Ravenstijn, Paulien;
Remmerie, Bart;
Savitz, Adam;
Samtani, Mahesh N.;
Nuamah, Isaac;
Chang, Cheng‐Tao;
De Meulder, Marc;
Hough, David;
Gopal, Srihari

Publication type:

Article

Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.

Published in:

2017

By:

Gopal, Srihari;
Lane, Rosanne;
Nuamah, Isaac;
Copenhaver, Margaret;
Singh, Jaskaran;
Hough, David;
Bach, Mark;
Savitz, Adam

Publication type:

journal article

An assessment of injection site reaction and injection site pain of 1‐month and 3‐month long‐acting injectable formulations of paliperidone palmitate.

Published in:

Perspectives in Psychiatric Care, 2018, v. 54, n. 4, p. 530, doi. 10.1111/ppc.12267

By:

Kern Sliwa, Jennifer;
Savitz, Adam;
Nuamah, Isaac;
Mathews, Maju;
Gopal, Srihari;
Elefant, Erica;
Najarian, Dean;
Alphs, Larry

Publication type:

Article